Related by context. All words. (Click for frequent words.) 66 PEG IFN 65 cEVR 64 rapid virologic response 63 Chronic Hepatitis C 62 rapid virological response 62 Phase 2b Clinical Trial 62 log# copies mL 61 Study Evaluating 61 Phase 2b Study 61 Pharmacokinetics PK 61 Viral Load 61 Orally Active 60 #mg QD [002] 60 Phase Ib Clinical Trial 60 Meets Primary Endpoint 60 PEG Interferon 60 HCV Genotype 60 Sustained Virologic Response 60 Trial Evaluating 60 Treated Patients 60 Pegylated Liposomal Doxorubicin 59 XIENCE V PROMUS Stent 59 virologic response EVR 59 Peginterferon 59 Phase IIb Clinical Trial 59 Initiate Phase 59 treatment naive genotype 59 Protease Inhibitors 59 Novel Inhibitor 59 Double Blind Randomized 59 inhibitor RG# 59 Median PFS 59 Plus Ribavirin 59 Commences Phase 59 log# reduction 59 Sustained virologic response 58 Achieves Primary Endpoint 58 Solid Tumors criteria 58 Peginterferon Alfa 2a 58 Pivotal Phase 58 HBeAg seroconversion 58 ara C 58 FOLFOX6 58 Prolongs Survival 58 stage IIIB 58 Phase IIa Trial 58 Adjuvant Treatment 58 BARACLUDE ® 58 Antiviral Therapy 58 Monotherapy 58 Kinase Inhibitor 57 severe neutropenia 57 q#h 57 Target Lesion Revascularization TLR 57 mL/min/#.# m 2 57 Phase 2b Trial 57 Follicular Lymphoma 57 Virologic 57 alfa 2a 57 Diffuse Large B 57 HCV genotype 57 Efficacy Trial 57 ug dose 57 Initiated Phase 57 CLL SLL 57 aspartate aminotransferase 57 Completes Patient Enrollment 57 SVR# 57 Protease Inhibitor 57 Omacetaxine 57 TPV r 57 gemcitabine carboplatin 57 Novel Oral 57 Antiviral Activity 57 Interferon Alfa 57 Pharmacokinetic Study 57 undetectable HCV RNA 57 liver histology 57 Severe Sepsis 57 log# IU mL 57 Patients Treated 57 Phase 2a Clinical Trial 57 VELCADE melphalan 57 HCV RESPOND 2 57 Hsp# Inhibitor 57 Significantly Improved 57 Phase IIb Trial 57 Cellular Immunotherapy 57 Phase IIa Clinical Trial 57 Clinical Trial Results 57 IU ml 57 Demonstrated Significant 57 Initiates Clinical Trial 56 Prognostic Significance 56 Pharmacodynamic 56 alanine aminotransferase ALT 56 Infected Patients 56 mg/m2 dose 56 Randomized Phase 56 sUA 56 Advanced Melanoma 56 Demonstrates Significant 56 ribavirin RBV 56 TMC# r 56 certolizumab 56 mg QD 56 Stent Restenosis 56 atazanavir ritonavir 56 Randomized Evaluation 56 treatment naïve genotype 56 relapsed refractory multiple myeloma 56 Target Vessel Revascularization 56 Single Dose 56 Tyrosine Kinase Inhibitor 56 ribavirin therapy 56 FDA Approvals 56 ertapenem 56 biochemical relapse 56 Tipranavir 56 Fungal Infections 56 Anti Tumor 56 sustained virological response 56 lumbar spine BMD 56 Statistically Significant 56 Platinol ® 56 aspartate aminotransferase AST 56 tipranavir r 56 achieved ACR# 56 beta 1a 56 virologic response 56 genotypic resistance 56 Treatment Naive 56 stage IIIb IV 56 liposomal formulation 56 undetectable HBV DNA 56 IU mL 56 Treatment Experienced 56 Pegylated Interferon 55 Phase 2a Trial 55 IND Application 55 #mg BID [003] 55 IFN α 55 lopinavir r arm 55 x ULN 55 Amplicor 55 Disease Progression 55 μg dose 55 relapsed MM 55 Preclinical Models 55 ACR# response 55 mRCC 55 ALT elevations 55 Reductase 55 Study Demonstrates 55 HCV SPRINT 55 Myelodysplastic Syndrome MDS 55 PegIFN 55 Demonstrates Potential 55 Is Well Tolerated 55 antiretroviral naïve 55 serum prostate 55 -#.# log# 55 piperacillin tazobactam 55 genotype 1b 55 Allogeneic 55 Potent Inhibitor 55 Nucleoside 55 recurrent NSCLC 55 Patient Enrollment 55 Fludarabine 55 serum ALT 55 Drug Candidate 55 HCV viral 55 Predict Response 55 mcg BID 55 Ejection Fraction 55 q8h 55 ritonavir boosted 55 Dose Escalation 55 Subtype 55 Posaconazole 55 Adjuvant Therapy 55 Clinical Trial Evaluating 55 Improves Outcomes 55 Patients Receiving 55 BENICAR HCT 55 Antiangiogenic 55 Aurora Kinase 55 Pivotal Study 54 mIU ml 54 TMC# [002] 54 Pivotal Trial 54 Combination Treatment 54 CRp 54 tumor xenograft models 54 Benign Prostatic Hyperplasia 54 plasma HCV RNA 54 HIV RNA 54 Cyclophosphamide 54 Free Survival PFS 54 virologic failures 54 HBeAg negative 54 Copegus ribavirin 54 HBeAg negative patients 54 alanine aminotransferase 54 #mg BID [001] 54 SGPT 54 Phase III Clinical Trial 54 cells mcL 54 REYATAZ r 54 nucleotide analog 54 ACTEMRA TM 54 annualized relapse 54 achieved statistical significance 54 HBeAg 54 Successfully Completes Phase 54 First Patient Dosed 54 ULORIC 54 HCV genotypes 54 Novel Compound 54 ABC/3TC 54 #mg BID [002] 54 fasting plasma glucose FPG 54 HBeAg positive 54 Investigational Drug 54 Plaque Psoriasis 54 metastatic hormone refractory 54 neurologic progression 54 SGOT 54 II Clinical Trial 54 Dose Escalation Study 54 abacavir lamivudine 54 Remission Maintenance 54 rizatriptan 54 RNA copies mL 54 Insulin Glargine 54 achieved CCyR 54 Bosentan 54 Lung Cancer Trial 54 transaminase 54 Crohn Disease Activity 54 Initiates Phase 2b 54 serum HBV DNA 54 Hepatic Encephalopathy 54 mg BID 54 evaluable subjects 54 progression TTP 54 virologic failure 54 Significantly Reduces 54 DLTs 54 alpha 2a 54 Diabetic Nephropathy 54 Initiates Clinical 54 Functional Dyspepsia 54 HCV Infection 54 investigational protease inhibitor 54 peginterferon alfa 2a 54 Elitek 54 Tolerability 54 undetectable hepatitis C 53 Respiratory Virus 53 binary restenosis 53 Multiple Myeloma MM 53 Naive Patients 53 serum triglycerides 53 efavirenz EFV 53 CCR5 tropic HIV 53 peginterferon alfa 2a #KD 53 Lenalidomide 53 ErbB2 positive 53 Multidrug Resistance 53 Conjugate 53 First Patient Enrolled 53 atazanavir sulfate 53 HLA A2 53 mucosal healing 53 Phase 2a Study 53 CCyR 53 Antitumor 53 Placebo Controlled Study 53 Chemotherapy Induced 53 Primary Endpoint 53 Initiates Phase II 53 NDA Submission 53 Cutaneous Melanoma 53 undetectable virus HCV 53 von Willebrand Factor 53 Metastatic Melanoma 53 ATV RTV 53 Peripheral Arterial 53 HCV genotype 1 53 Shows Promising 53 DR4 53 F FDG PET 53 MADRS score 53 Phase 1b Clinical Trial 53 albumin excretion rate 53 Chronic Lymphocytic Leukemia 53 Phase III Trial 53 lopinavir r 53 HbA 1c levels 53 lactate dehydrogenase LDH 53 TH# [003] 53 Watchful Waiting 53 plus dexamethasone 53 prednisone VcMP 53 HBV DNA levels 53 Clinical Outcome 53 Demonstrates Statistically Significant 53 Partial Response 53 cells uL 53 Pemetrexed 53 dose cohort 53 serum phosphate 53 iPTH 53 Files IND 53 Left Ventricular 53 CIMZIA ™ 53 sustained virologic response 53 Files Investigational 53 MDA MB 53 CIMZIA TM 53 Risk Stratification 53 Saquinavir 53 selective agonist 53 Glatiramer Acetate 53 Interferon Alpha 53 AEGR 53 E1 INT TM 53 Significantly Improves 53 NMIBC 53 Confirmatory Phase 53 recurrent genital herpes 53 Unfractionated Heparin 53 adalimumab Humira 53 Combination Therapy 53 Improves Survival 53 Myeloid 53 nucleoside analog 53 dapagliflozin plus 53 Bacteremia 53 CC genotype 53 mU liter 53 pulmonary exacerbations 53 PegIFN RBV 53 Hepatocellular Carcinoma 53 Pegasys plus Copegus 53 Contrast Enhancement 53 Antiplatelet 52 naïve HCV 52 glycosylated hemoglobin 52 gemcitabine cisplatin 52 Thrombotic 52 Androgen Independent 52 Receptor Agonist 52 pegIFN 52 Cardiac Troponin 52 Clostridium difficile Infection 52 Epithelial Cell 52 Dose Ranging Study 52 Multiple Ascending Dose 52 Cmax 52 ug mL 52 Alagebrium 52 bendamustine 52 Showed Significant 52 HOMA IR 52 Hypercholesterolemia 52 cells μL 52 complete cytogenetic response 52 Infarct 52 baseline LDH 52 Darusentan 52 μmol L 52 Small Molecule Inhibitors 52 Investigational Treatment 52 serum urate 52 Apolipoprotein 52 Receptor Antagonists 52 endoscopic remission 52 hematological parameters 52 2DR 52 AST ALT 52 mIU mL 52 IIa Clinical Trial 52 REYATAZ r arm 52 lymphocytosis 52 FOLFOX4 52 Demonstrates Efficacy 52 Pegasys ® 52 seropositivity 52 HGPIN 52 leucopenia 52 statistical significance p 52 Randomised 52 Peg IFN 52 oxycodone CR 52 Orthostatic Hypotension 52 Shows Efficacy 52 Darunavir 52 serum HCV RNA 52 mg kg dose 52 Prognostic Index 52 Treating Chronic 52 Well Tolerated 52 Integrase Inhibitor 52 rs# [001] 52 Milestone Payments 52 HCV RNA 52 LPV r 52 IIIa inhibitor 52 Kidney Function 52 COMBIVIR 52 ALT AST 52 Taxane 52 Schizophrenia Treatment 52 fosamprenavir 52 cTnI 52 IPSS 52 Amrubicin 52 Hb A1C 52 chlorambucil 52 blood phenylalanine Phe 52 Severity Scale 52 CR CRu 52 Supplemental Figure 52 antigen PSA levels 52 viral kinetics 52 creatine kinase CK 52 Transdermal Patch 52 null responders 52 LEXIVA r 52 oral allopurinol 52 corticosteroid dose 52 glycated hemoglobin levels 52 HBV DNA 52 Hypertensive Patients 52 undetectable viral load 52 NRTI resistance 52 HBeAg positive patients 52 TIMP 1 52 fluvastatin 52 Diastolic Heart Failure 51 dasatinib Sprycel 51 dose melphalan 51 Anticancer Drug 51 pharmacokinetics PK 51 CCR5 antagonist 51 Receptor Antagonist 51 corrected QT interval 51 MabCampath 51 HPV-#/# 51 AUCs 51 Adalimumab 51 elevated ALT 51 Main Outcome Measure 51 Ischemic Stroke 51 Flu Cy 51 metastatic CRC 51 neutrophil count 51 nucleoside naive 51 Inhaled Corticosteroids 51 pegylated interferon alpha 51 detectable HCV RNA 51 C Reactive Protein 51 Virus Infection 51 Randomized Placebo Controlled Trial 51 seropositive patients 51 Combo Therapy 51 peginterferon alfa 2b 51 Randomized Clinical Trials 51 Pulmonary Arterial Hypertension 51 regulated kinase 51 bivalirudin monotherapy 51 somatostatin analog 51 mmHg diastolic 51 CrCl 51 ACR# responses 51 Anti CD# Antibody 51 viral titers 51 monoinfected 51 p = #.# [003] 51 Dose Ranging 51 pg ml 51 TAXUS Stent 51 unresectable stage 51 resected pancreatic cancer 51 5-FU/LV 51 Platelet Aggregation 51 T2DM 51 amprenavir 51 Kinoid 51 AZT zidovudine Retrovir 51 virological response 51 Melphalan 51 interferon ribavirin 51 Allergic Rhinitis 51 Hematological Malignancies 51 Diabetic Neuropathy 51 Gastric Cancer 51 boosted atazanavir 51 pegylated interferon alfa 2a 51 Cinacalcet 51 CsA 51 DAS# [002] 51 Mesh Matrix 51 % CI #.#-#.# [003] 51 Index CDAI 51 mm Stent 51 Lupus Drug 51 Oral Formulation 51 Chemotherapy Improves 51 Telbivudine 51 ALT normalization 51 Binding Protein 51 Tumor Necrosis Factor 51 blood Phe 51 pCR 51 Epoetin 51 metastatic renal cell carcinoma 51 Therapeutic Antibody 51 Lubiprostone 51 TIMP 51 Transthyretin 51 EGFR TKI 51 Immunotherapeutic 51 null mice 51 sorafenib Nexavar 51 hepatic fibrosis 51 Pivotal Trials 51 untreated multiple myeloma 51 Alkaline Phosphatase 51 beta2 51 triglycerides TG 51 :2 51 ritonavir boosted lopinavir 51 REG2 51 plus methotrexate 51 HER2 overexpressing 51 seminal vesicle invasion 51 Intraocular Pressure 51 Systolic Blood Pressure 51 normal ULN 51 HBsAg 51 oral FTY# 51 ZACTIMA 51 pyrazinamide 51 posaconazole 51 CK MB 51 Randomized Clinical Trial 51 protease inhibitor PI 51 coinfected 51 serum phosphorous 51 Neoadjuvant Chemotherapy 51 Oral Spray 51 Non Inferiority 51 Dose Response 51 oblimersen 51 QTcF 51 STELARA ® 51 #mg QD [001] 51 IIIa inhibitors 51 Traficet EN 51 dosing cohorts 51 Active Ulcerative Colitis 51 pegylated interferon alfa 51 REYATAZ ® 51 antibody titer 51 Endocrine Therapy 51 5alpha reductase 51 FTC TDF 51 nonnucleoside reverse transcriptase inhibitors 50 undetectable viral 50 K ras mutations 50 Hazard Ratio 50 DAS# remission 50 Fewer Side Effects 50 FOLPI 50 isoprostane 50 Community Acquired Pneumonia 50 QT Prolongation 50 Submits NDA 50 telaprevir dosed 50 Transdermal Delivery 50 plus COPEGUS 50 serum phosphorus 50 apolipoprotein B 50 Pharmaceuticals Initiates 50 fludarabine cyclophosphamide 50 fasting plasma glucose 50 Combination Clinical Trial 50 sitaxsentan 50 Nasdaq Notice Regarding 50 mITT population 50 Non Invasive Treatment 50 CDAI 50 Left Atrial 50 APTIVUS 50 antiviral efficacy 50 cancer mCRC 50 #mg/m# [002] 50 PSADT 50 glycosylated hemoglobin levels 50 gefitinib Iressa 50 Antiretroviral Therapy 50 lymphopenia 50 pmol L 50 Nephropathy 50 DOXIL 50 lumiliximab 50 somatostatin analogue 50 Atopic Dermatitis 50 CD# CD# 50 ischemia driven 50 copies mL 50 CDAI score 50 Rheumatoid Arthritis Patients 50 beta3 50 administered subcutaneously 50 nucleoside naive patients 50 multicentre randomized 50 Angiogenic 50 Study Showed 50 Desvenlafaxine Succinate 50 Rheumatoid 50 dose cytarabine 50 Mitigates 50 Boceprevir 50 Parainfluenza 50 Insulin Resistance 50 ATAC Arimidex Tamoxifen Alone 50 LV ejection fraction 50 Nodular 50 Natalizumab 50 Therapeutic Vaccine 50 FOLFIRI 50 PSA nadir 50 Artery Disease 50 creatinine ratio 50 VGPR 50 tenofovir disoproxil fumarate Viread 50 virologic suppression 50 RRM1 50 Cardiotoxicity 50 refractory NSCLC 50 reflux esophagitis 50 HAM D# scores 50 seronegative 50 liver enzymes ALT 50 mcg mL 50 plasma renin activity 50 Carotid Artery Stenting 50 RU EEU EUROPE ASIA 50 Forodesine 50 chronic HCV infection 50 serum calcium levels 50 Glycosylation 50 refractory follicular lymphoma 50 efficacy endpoint 50 mg ustekinumab 50 F FLT 50 Rear Suspension 50 HCV replicon 50 Phase 1a 50 KRAS wild 50 Novel Mechanism 50 neutrophil counts 50 EP4 50 Potent Anti 50 diastolic velocity 50 tipranavir 50 selectively binds 50 doxorubicin docetaxel 50 Novel Therapeutic 50 Myoblast 50 Data Suggest 50 PLAT 50 MAXIMA 50 Gleevec resistant 50 renal artery stenting 50 Myelofibrosis 50 HER2 Positive Breast Cancer 50 transaminases 50 Xalatan R 50 colorectal adenoma 50 Diabetic Patients 50 log# 50 Interferon Gamma 50 thyroglobulin 50 prior chemotherapy regimens 50 viral load 50 RPTP 50 IMPACT IMmunotherapy 50 plasma uric acid 50 Phase IIA 50 Clinical Efficacy 50 Subgroup Analysis 50 Plasma concentrations 50 Appears Safe 50 tirofiban 50 diabetes mellitus DM 50 Tiotropium 50 -2 -3 50 GSTP1 50 Tolerability Study 50 CIBIC plus 50 azacytidine 49 Low Dose 49 aminotransferase ALT 49 Coronary Arteries 49 lispro 49 2 microglobulin 49 HbA 1c 49 tapentadol ER 49 Shows Promise Against 49 International Prostate Symptom 49 reductase inhibitor 49 FDA defined valvulopathy 49 disease progression TTP 49 selective adenosine 49 FDA Okays 49 serum urate levels 49 copies ml 49 moderate renal impairment 49 Demonstrate Significant 49 Phase III Trials 49 del 5q 49 NPH insulin 49 fasting plasma 49 Teriflunomide 49 noninferiority 49 hemoglobin A1c HbA1c 49 receiving VICTRELIS 49 Tyrosine Kinase 49 plasma pharmacokinetics 49 IgA antibody 49 1beta 49 serum concentrations 49 dosage regimens 49 combination antiretroviral therapy 49 Main Outcome Measures 49 baseline HbA1c 49 Treatment Naive HIV 49 Polymorphisms 49 neoadjuvant 49 Kaplan Meier estimates 49 Dehydrogenase 49 standard chemotherapy regimen 49 ZD# [001] 49 interferon alfa 2a 49 PARP Inhibitor 49 K#N 49 Recurrent Glioblastoma 49 HLA DR4 49 Macrophage 49 antiretroviral naive 49 Catenin 49 ERalpha 49 ng dL 49 TRUS 49 clinically meaningful improvement 49 pharmacodynamic PD 49 lymphocyte counts 49 Occluded 49 HCV 49 Further Validates 49 secondary efficacy endpoints 49 ibandronate 49 associated vasculitis 49 Estrogen Receptor 49 ACR# [002] 49 metastatic malignant melanoma 49 Embolic 49 Topotecan 49 Figure S4 49 Chemoradiation 49 Tablet Formulation 49 interleukin IL -# 49 Diabetic Foot Ulcer 49 HbA1c levels 49 Clinical Evaluation 49 diameter stenosis 49 Novel Antibiotic 49 Randomized Trials 49 plus MTX 49 Randomised Controlled Trial 49 prostate cancer CRPC 49 Viral load 49 Lung Cancer Drug 49 ^ sup #m 49 Troponin T 49 Liraglutide Effect 49 radical prostatectomy RP 49 darunavir r 49 μg liter 49 unresectable 49 Virulizin ® 49 docetaxel chemotherapy 49 #A# #A# 49 tenofovir emtricitabine 49 cytogenetic response 49 HT 1A 49 TGZ 49 STELARA 49 Anti VEGF 49 mCRC patients 49 ^ Tc 49 SUMMARY NOTICE OF 49 mcg kg 49 μg mL 49 P#Y# [001] 49 Clinical Trial Data 49 eplerenone 49 serum aminotransferase levels 49 intact parathyroid hormone 49 pegylated interferon alfa 2b 49 mg RDEA# 49 inflammatory biomarkers 49 FIRMAGON 49 specific antigen PSA 49 Tumor Cell 49 hematologic toxicity 49 recurrent VTE 49 -#.# log# copies mL 49 Successfully Completed 49 adriamycin 49 Retinal Vein Occlusion 49 Clinical Study Shows 49 carboplatin paclitaxel 49 tPSA 49 hepatic insulin sensitivity 49 Phase IIB 49 STRAT 49 SOHC Automatic 49 Ribavirin 49 STENT 49 boosted protease inhibitor 49 Granulocyte Colony Stimulating Factor 49 Clinical Remission 49 Diamyd Medical Diamyd 49 variant allele 49 Systemic Delivery 49 promoter methylation 49 pharmacokinetic PK profile 49 -Vir ginia 49 Susceptibility Testing 49 Herpes Simplex Virus 49 palifosfamide Zymafos TM 49 virological failure 49 Improve Survival 49 EGFR mutation positive 49 triiodothyronine 49 lamivudine refractory patients 49 atorvastatin #mg 49 IRLS score 49 Polymorphism 49 Key Milestones 49 antidiabetic drug 49 Insulin Therapy 49 aPTT 49 Febuxostat 49 Kaplan Meier analysis 49 aminotransferases 49 CELGENE 49 pg mL 49 docetaxel Taxotere ® 49 KSP inhibitors 49 Impaired glucose tolerance 49 gout flares 49 Renal Cancer 49 SCH # 48 Sustained Virological Response 48 Disease Modifying 48 febrile neutropenia 48 Critically Ill Patients 48 Skin Irritation 48 chronic HCV 48 gene polymorphism 48 r2 = 48 Lp PLA 2 48 eculizumab therapy 48 Oral Calcitonin 48 serum potassium 48 lactate dehydrogenase 48 infliximab monotherapy 48 NRTI 48 platelet reactivity 48 Begin Clinical Trials 48 Genes Predict 48 μg ml 48 GFAP 48 hepatocellular carcinomas 48 #mg dose [002] 48 Study Shows Significant 48 previously untreated follicular 48 Slow Progression 48 RU EUROPE EEU EMRG 48 median CD4 48 International Prognostic Scoring 48 Results Confirm 48 locoregional disease 48 glucuronide 48 Lung Tumors 48 glycosylated hemoglobin HbA1c 48 Breast Cancer Recurrence 48 Induces 48 atazanavir Reyataz 48 Imatinib 48 Spectrum Pharmaceuticals Announces 48 heavily pretreated 48 LANTUS R 48 creatinine clearance 48 cytokeratin 48 multivariate Cox 48 Synthetic Peptide 48 Hepatitis C Treatment 48 REMICADE monotherapy 48 remission CR 48 ibritumomab tiuxetan 48 CYP#A# substrate 48 hepatoma 48 dose dexamethasone 48 FDG uptake 48 intravascular hemolysis 48 trough FEV1 48 NS3 48 PEG interferon 48 Cloretazine 48 austriamicrosystems Introduces 48 Quantitation 48 SUVmax 48 IMPACT DCM 48 Anti TNF 48 mg subcutaneous 48 PegIntron 48 Bulk Sampling Program 48 syngeneic 48 Lung Injury 48 rs# [004] 48 Announces Ticker Symbol 48 #.#ng/ml 48 POL PRO 48 Viread Emtriva 48 Synthase 48 viraemia 48 Platelet Function 48 NATRECOR ® 48 Tonnes Ni 48 fluticasone propionate FP 48 FDG PET imaging 48 APTIVUS R 48 APOPTONE 48 abiraterone acetate 48 Erosive Esophagitis 48 immunostaining 48 #beta hydroxysteroid dehydrogenase 48 low dose ritonavir 48 IDDM 48 Lipoprotein 48 mcg albinterferon alfa 2b 48 darunavir ritonavir 48 acyltransferase 48 Immunosuppression 48 symptomatic hypoglycemia 48 deoxy 48 median PFS 48 transdermal estradiol 48 ABCB1 48 triglyceride concentrations 48 Symptom Scale 48 Milestone Payment 48 subcutaneously administered 48 CD4 + cell 48 oral diclofenac 48 integrin alpha 48 Symptom Severity 48 Breast Cancer Cells 48 unfavorable cytogenetics 48 QTc 48 Lysis 48 #P [004] 48 serum testosterone 48 Phase 2a trial 48 U# [007] 48 Replacement Therapy 48 dose dependently 48 Pulmonary Artery 48 Molecular Weight Heparin 48 -Bairagi 48 Drug Fails 48 nab paclitaxel 48 response CCyR 48 IgA Nephropathy 48 urine albumin 48 aminotransferase levels 48 Lupuzor ™ 48 IL#B 48 KRAS mutations occur 48 OGTT